Viking Therapeutics (VKTX) Long-Term Debt Issuances (2014 - 2017)
Viking Therapeutics (VKTX) posted Long-Term Debt Issuances of $200000.0 for Q3 2017, up 100.0% sequentially from $100000.0 in Q2 2017.
Powered by 
Analysis
Viking Therapeutics (VKTX) Long-Term Debt Issuances (2014 - 2017) Analysis & Trends
Viking Therapeutics has reported Long-Term Debt Issuances for 2 years, with the latest figure at $200000.0 in Q3 2017.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $200000.0 in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $1.5 million (changed N/A YoY) and the FY2016 annual result came in at $300000.0, changed N/A from the prior year.
- Long-Term Debt Issuances rose to $200000.0 in Q3 2017 per VKTX's latest filing, from $100000.0 in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $750000.0 in Q3 2014 and troughed at $100000.0 in Q2 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Viking Therapeutics | 4.01 Bn | 4.01 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 200,000.00 |
| Jun 30, 2017 | 100,000.00 |
| Dec 31, 2014 | 500,000.00 |
| Sep 30, 2014 | 750,000.00 |